Phase I study of everolimus in pediatric patients with refractory solid tumors.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Oncology

• Publication date

  2007-10-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2007.11.4017PMID 17947729
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

  2007cited by this paper
• Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

  2007cited by this paper
• A perivascular niche for brain tumor stem cells.

  2007cited by this paper
• Therapeutic targets: MTOR and related pathways

  2006cited by this paper
• Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor

  2006cited by this paper
• PIK3CA mutations in breast cancer are associated with poor outcome

  2006cited by this paper
• Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.

  2006cited by this paper
• TOR signaling in growth and metabolism.

  2006cited by this paper
• Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

  2006cited by this paper
• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

  2006cited by this paper
• Hypoxia-induced energy stress regulates mRNA translation and cell growth.

  2006cited by this paper
• Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

  2006cited by this paper
• Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.

  2006cited by this paper
• Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.

  2006cited by this paper
• Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

  2005cited by this paper
• Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

  2005cited by this paper
• Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

  2005cited by this paper
• The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

  2005cited by this paper
• Growing roles for the mTOR pathway.

  2005cited by this paper
• Clinical Pharmacokinetics of Everolimus

  2004cited by this paper
• Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.

  2004cited by this paper
• Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells

  2004cited by this paper
• mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

  2004cited by this paper
• The tor pathway: a target for cancer therapy

  2004cited by this paper
• Simultaneous determination of four immunosuppressants by means of high speed and robust on-line solid phase extraction-high performance liquid chromatography-tandem mass spectrometry.

  2004cited by this paper
• The LKB1 tumor suppressor negatively regulates mTOR signaling.

  2004cited by this paper
• Medulloblastoma Sensitivity to 17-Allylamino-17-demethoxygeldanamycin Requires MEK/ERK*

  2003cited by this paper
• Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

  2002cited by this paper
• Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

  2001cited by this paper
• Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

  2001cited by this paper
• Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• PIK3CA is implicated as an oncogene in ovarian cancer

  1999cited by this paper
• Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor.

  1999cited by this paper
• Studies on the mechanism of resistance to rapamycin in human cancer cells.

  1998cited by this paper
• Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma.

  1997cited by this paper
• PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

  1997cited by this paper
• Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor.

  1994cited by this paper

• mTOR blockade mitigates chemotherapy drug-induced intestinal toxicity via inhibition of pyroptosis.

  2025cites this paper
• Pharmacological Phase I Clinical Trials in Pediatric Brain Tumors (1990–2024): A Historical Perspective

  2025cites this paper
• Current advances in the management of atypical teratoid rhabdoid tumors (ATRT).

  2025cites this paper
• Hepatotoxicity Mechanisms of Sirolimus and Everolimus Unveiled Through Metabolomics and Transcriptomics Analysis.

  2025cites this paper
• A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors

  2025cites this paper
• Freeze-thawed electrosprayed everolimus loaded nanoparticles as a potential drug delivery system in brain tumours: Design and Characterisation

  2024cites this paper
• Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.

  2024cites this paper
• Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

  2024cites this paper
• Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single‐institution retrospective analysis

  2023cites this paper
• Toxic effects of sirolimus and everolimus on the development and behavior of zebrafish embryos.

  2023cites this paper
• Population pharmacokinetics of everolimus in patients with seizures associated with focal cortical dysplasia

  2023cites this paper
• Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study

  2023cites this paper
• Phase II study of everolimus for recurrent or progressive pediatric ependymoma

  2023cites this paper
• High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

  2023cites this paper
• Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report

  2022cites this paper
• Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer

  2022cites this paper
• Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience

  2022cites this paper
• Recent Update in Pharmacological Agents for Optic Pathway Glioma

  2022cites this paper
• Ion Channel Drugs Suppress Cancer Phenotype in NG108-15 and U87 Cells: Toward Novel Electroceuticals for Glioblastoma

  2022cites this paper
• Drug penetration in pediatric brain tumors: Challenges and opportunities

  2021cites this paper
• Deficiency in the Treatment Description of mTOR Inhibitor Resistance in Medulloblastoma, a Systematic Review

  2021cites this paper
• Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

  2021cites this paper
• Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial

  2021influential citation
• A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study

  2021cites this paper
• Systematic Review of Recurrent Osteosarcoma Systemic Therapy

  2021cites this paper
• Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

  2021cites this paper
• A phase II study continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study

  2020cites this paper
• A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors

  2020cites this paper
• Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities

  2020cites this paper
• Pediatric Osteosarcoma: Connecting Present and Future Approaches to Diagnosis and Treatment

  2020cites this paper
• A Phase II Study of Continuous Oral mTOR Inhibitor Everolimus for Recurrent, Radiographic-Progressive Neurofibromatosis Type 1-Associated Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials Consortium Study.

  2020cites this paper
• SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers

  2020cites this paper
• A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low‐grade glioma

  2020cites this paper
• A phase II study continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study

  2020cites this paper
• Upfront treatment with mTOR inhibitor everolimus in pediatric low‐grade gliomas: A single‐center experience

  2020influential citation
• Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.

  2020cites this paper
• Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.

  2019cites this paper
• Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors

  2019cites this paper
• Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

  2019cites this paper
• Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin

  2018cites this paper
• Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse

  2018cites this paper
• Lack of value of juvenile animal toxicity studies for supporting the safety of pediatric oncology phase I trials

  2018cites this paper
• Phase I trial of the mTOR inhibitor everolimus in combination with multi‐agent chemotherapy in relapsed childhood acute lymphoblastic leukemia

  2018cites this paper
• Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project

  2017cites this paper
• ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo

  2017cites this paper
• Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

  2017cites this paper
• A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

  2017cites this paper
• The Collagen Gel Droplet–embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma

  2017cites this paper
• Prediction of Apparent Oral Clearance of Small-Molecule Inhibitors in Pediatric Patients.

  2017cites this paper
• The effects of selective inhibitors of N-Glycosylation and Endoplasmic Reticulum stress inducers on Neuroblastoma cell proliferation and Apoptosis

  2017cites this paper
• A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials

  2017cites this paper
• ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.

  2017cites this paper
• Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

  2016cites this paper
• Targeting Oncoproteins for Molecular Cancer Therapy

  2016cites this paper
• Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma

  2016cites this paper
• Targeted Drugs in Pediatric Oncology

  2016cites this paper
• The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors

  2016cites this paper
• A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

  2016cites this paper
• On the use of juvenile animal studies to support oncology medicine development in children.

  2016cites this paper
• Brainstem Glioma in Adults

  2016cites this paper
• Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma

  2016cites this paper
• Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors

  2016cites this paper
• Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma

  2016cites this paper
• Cell Proliferation in Neuroblastoma

  2016cites this paper
• Review of Osteosarcoma and Current Management

  2016cites this paper
• The pharmacogenomics of osteosarcoma

  2016cites this paper
• Experimental Therapeutic Trial Design for Pediatric Brain Tumors

  2016cites this paper
• Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma

  2016cites this paper
• Medulloblastoma development: tumor biology informs treatment decisions.

  2015cites this paper
• Novel Therapies on the Horizon

  2015cites this paper
• Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment

  2015cites this paper
• Targeted Therapies in Paediatric Brain Tumours

  2015cites this paper
• Molecular Biology of Pediatric Brain Tumors and Impact on Novel Therapies

  2015cites this paper
• New therapeutic targets in Ewing sarcoma: from pre-clinical proof-of-concept to clinical trials

  2015cites this paper
• PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma

  2015cites this paper
• Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study

  2015cites this paper
• Translating genomic discoveries to the clinic in pediatric oncology

  2015cites this paper
• A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput format

  2015cites this paper
• Advances in emerging drugs for osteosarcoma

  2015cites this paper
• Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas

  2015cites this paper
• Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy.

  2015cites this paper
• Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma

  2015cites this paper
• Treatment-related fatigue with everolimus and temsirolimus in patients with cancer—a meta-analysis of clinical trials

  2015cites this paper
• Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001.

  2014cites this paper
• The rationale for targeted therapies in medulloblastoma.

  2014cites this paper
• Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.

  2014cites this paper
• mTOR Pathway As a Potential Target In a Subset of Human Medulloblastoma

  2014cites this paper
• A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report

  2014cites this paper
• Advances in paediatric cancer treatment.

  2014cites this paper
• A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.

  2014cites this paper
• Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis.

  2014cites this paper
• Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL)

  2013cites this paper
• A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors

  2013influential citation
• Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration

  2013cites this paper
• A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.

  2013cites this paper
• Future of clinical genomics in pediatric oncology.

  2013cites this paper
• A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.

  2013cites this paper
• A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A children's oncology group phase 1 consortium study

  2013cites this paper
• Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?

  2013cites this paper
• Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery

  2013cites this paper